MSDASCO 2019 - data

terça-feira, 28 maio 2019 14:33
Atualidade

Contribuição portuguesa na ASCO 2019

Entre os 40 mil participantes de Oncologia de países de todos os continentes que estarão na ASCO 2019, em Chicago, também Portugal estará representado por profissionais com trabalhos aceites na ASCO, ou com presença no programa, e por especialistas portugueses que abraçaram a carreira internacional e hoje desenvolvem investigação além-fronteiras.

Assinalamos aqui contributo de especialistas portugueses no programa da ASCO 2019, para que possa seguir os respetivos trabalhos.

DIA 1

CLINICAL SCIENCE SYMPOSIUM

 Next-Generation Therapeutics and Biomarkers in Melanoma

Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.

Ines Pires da Silva

Melanoma Institute Australia

1 de junho, 3:48 - 4:00, sala S100bc

POSTER DISCUSSION SESSION

Genitourinary (Prostate) Cancer

Chair(s): Pedro C. Barata,

Tulane University;

Dana E. Rathkopf,

Memorial Sloan Kettering Cancer Center

1 de junho, 4:30 - 6:00, sala Arie Crown Theater

DIA 2

POSTER SESSION

Breast Cancer—Metastatic

Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC)

Mafalda Oliveira

Vall d'Hebron University Hospital

Poster Board: #156

2 de junho, 8:00 - 11:00, Hall A

POSTER SESSION

Breast Cancer—Local/Regional/Adjuvant

Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.

Arlindo R. Ferreira

Institut Gustave Roussy

Poster Board: #4

2 de junho, 8:00 - 11:00, Hall A

Discussão de poster: 2 de junho, 4:30-6:00, Hall D2

POSTER SESSION

Breast Cancer—Local/Regional/Adjuvant

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

Fatima Cardoso

Champalimaud Clinical Center

Poster Board: #90b

2 de junho, 8:00 - 11:00, Hall A

POSTER SESSION

Breast Cancer—Local/Regional/Adjuvant

The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.

Isabel Pimentel

Mount Sinai Hospital- University of Toronto

Poster Board: #21

2 de junho, 8:00 - 11:00, Hall A

DIA 3

EDUCATION SESSION

Management of Uncommon and Rare Breast Cancers

Male Breast Cancer

Fátima Cardoso

Champalimaud Clinical Center

3 de junho, 8:40 - 9:00, | sala S100bc

POSTER SESSION

Gastrointestinal (Noncolorectal) Cancer

Homologous recombination deficiency as prognostic marker in metastatic gastric cancer.

Nuno Sousa

Instituto Português de Oncologia do Porto (IPO Porto)

Poster Board: #145

3 de junho, 8:00 - 11:00, Hall A

POSTER SESSION

Gastrointestinal (Noncolorectal) Cancer

Molecular profile of ampulla of vater carcinoma (AVC): A rare tumor type with meaningful molecular alterations.

João Pinto

Hospital Beatriz Ângelo

Poster Board: #224

3 de junho, 8:00 - 11:00, Hall A

EPOSTERS

Breast Cancer—Local/Regional/Adjuvant

Biological behavior of HER2+ breast cancer: Differences based in hormone receptor expression.

Maria João Ribeiro da Silva

Instituto Português de Oncologia do Porto (IPO Porto)

Abstract No: e12120

EPOSTERS

Developmental Immunotherapy and Tumor Immunobiology

Development of a novel dendritic cell-based immunotherapy targeting cancer stem cells.

João Calmeiro

Universidade de Coimbra

Abstract No: e14009

Subscrever Newsletter do Congresso

Agenda

mai31
13:00
S504
mai31
14:45
100bc
mai31

Área Reservada